Next Article in Journal
Erratum: Legalizing Euthanasia or Assisted Suicide: The Illusion of Safeguards and Controls
Previous Article in Journal
Solitary Fibrous Tumour Presenting as a Pedunculated Lung Mass with Associated Lung Atresia: Report of a Case
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 3
10.3747/co.19.908
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation

by
M. Ong
1,
K. Kwan
2,
S. Kamel–Reid
3 and
M. Vincent
1,*
1
Department of Oncology, London Health Sciences Centre, London, ON, Canada
2
Department of Pathology, London Health Sciences Centre, London, ON, Canada
3
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(3), 222-226; https://doi.org/10.3747/co.19.908
Submission received: 6 March 2012 / Revised: 4 April 2012 / Accepted: 2 May 2012 / Published: 1 June 2012

Abstract

The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIS) is evolving, as is an understanding of predictive biomarkers for tumour response in non-small-cell lung cancer (NSCLC). In this report, we describe a case of rapidly progressing, borderline-resectable, clinical stage IIIA (micro) papillary adenocarcinoma in a 78-year-old woman who experienced a profound response to neoadjuvant erlotinib without short-term toxicity. On EGFR mutation testing, this patient had an uncommon activating point mutation at L861Q in exon 21. Her response permitted successful surgical resection with negative margins and avoidance of chemoradiation, which she was deemed too frail to tolerate. Our case addresses unique management issues such as preoperative testing for EGFR mutation, utility of histology in predicting EGFR mutations, and use of egfr-tkis pre- and postoperatively for potentially resectable NSCLC.
Keywords: papillary adenocarcinoma; EGFR; erlotinib; neoadjuvant papillary adenocarcinoma; EGFR; erlotinib; neoadjuvant

Share and Cite

MDPI and ACS Style

Ong, M.; Kwan, K.; Kamel–Reid, S.; Vincent, M. Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation. Curr. Oncol. 2012, 19, 222-226. https://doi.org/10.3747/co.19.908

AMA Style

Ong M, Kwan K, Kamel–Reid S, Vincent M. Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation. Current Oncology. 2012; 19(3):222-226. https://doi.org/10.3747/co.19.908

Chicago/Turabian Style

Ong, M., K. Kwan, S. Kamel–Reid, and M. Vincent. 2012. "Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation" Current Oncology 19, no. 3: 222-226. https://doi.org/10.3747/co.19.908

APA Style

Ong, M., Kwan, K., Kamel–Reid, S., & Vincent, M. (2012). Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation. Current Oncology, 19(3), 222-226. https://doi.org/10.3747/co.19.908

Article Metrics

Back to TopTop